B
Bercedis L. Peterson
Researcher at Duke University
Publications - 124
Citations - 13873
Bercedis L. Peterson is an academic researcher from Duke University. The author has contributed to research in topics: Fludarabine & Randomized controlled trial. The author has an hindex of 51, co-authored 124 publications receiving 13349 citations. Previous affiliations of Bercedis L. Peterson include Durham University & Ohio State University.
Papers
More filters
Journal ArticleDOI
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
Lewis R. Silverman,Erin P. Demakos,Bercedis L. Peterson,Alice B. Kornblith,Jimmie C. Holland,Rosalie Odchimar-Reissig,Richard Stone,Douglas A. Nelson,Bayard L. Powell,Carlos M. DeCastro,John Ellerton,Richard A. Larson,Charles A. Schiffer,James F. Holland +13 more
TL;DR: Aza C treatment results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival compared with supportive care.
Journal ArticleDOI
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
Kanti R. Rai,Bercedis L. Peterson,Frederick R. Appelbaum,Jonathan E. Kolitz,Laurence Elias,Lois E. Shepherd,John D. Hines,Gregory Threatte,Richard A. Larson,Bruce D. Cheson,Charles A. Schiffer +10 more
TL;DR: When used as the initial treatment for chronic lymphocytic leukemia, fludarabine yields higher response rates and a longer duration of remission and progression-free survival than chlorambucil.
Journal ArticleDOI
The Cook-Medley hostility scale: item content and ability to predict survival.
TL;DR: The sum of the three predictive subsets was a better predictor than the full Ho scale, suggesting that it may be possible to refine the scale and achieve an even more effective measure of those aspects of hostility that are deleterious to health.
Journal ArticleDOI
Religiosity and Remission of Depression in Medically Ill Older Patients
TL;DR: This is the first report in which religiosity has been examined as a predictor of outcome of depressive disorder, and greater intrinsic religiosity independently predicted shorter time to remission.
Journal ArticleDOI
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
John C. Byrd,Bercedis L. Peterson,Vicki A. Morrison,Kathleen Park,Robert Jacobson,Eva Hoke,James W. Vardiman,Kanti R. Rai,Charles A. Schiffer,Richard A. Larson +9 more
TL;DR: Rituximab administered concurrently with fludarabine in previously untreated CLL patients demonstrates marked clinical efficacy and acceptable toxicity and Phase 3 studies using this combination approach for patients with CLL are warranted.